We invest in our partners early on, working side by side in optimizing their processes to derisk their path to the clinic faster. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health.
-
Industry
-
Biotechnology
-
Company size
-
51-200 employees
-
Headquarters
-
Rockville, Maryland
-
Type
-
Public Company
-
Founded
-
1999
-
Specialties
-
Vaccine Development, Protein Production, Transfection, Cell Therapy, Gene Therapy, Cancer, Immunotherapy, Electroporation, MyExpertPlatform, Tcell, NKcell, Bispecifics, Gene Editing, Cancer Research, Immuno-oncology, Stem Cell, CARMA, Cell Engineering, Biotechnology, Life Sciences, and Innovation